|
186 Companies |
|
244 Products |
|
244 Products |
|
91 Mechanisms of Action |
|
17 Trials |
|
2576 News |
|
| «12...678910111213141516...5253» |
- New trial: Regional Central Database Recording of Chronic Myeloid Leukemia (clinicaltrials.gov) - Aug 15, 2016
P=N/A, N=400, Recruiting, Sponsor: Institut Bergoni
- Aphexda (motixafortide) / BioLineRx
Enrollment change, Trial initiation date, Trial withdrawal: Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia (clinicaltrials.gov) - Aug 15, 2016
P1/2, N=0, Withdrawn, Sponsor: Sheba Medical Center
N=24 --> 0 | Initiation date: May 2014 --> Nov 2014 | Not yet recruiting --> Withdrawn
- Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy: Ruxolitinib in Combination With Autotransplant (clinicaltrials.gov) - Aug 12, 2016
P=N/A, N=0, Withdrawn, Sponsor: Marina Kremyanskaya
N=24 --> 0 | Initiation date: May 2014 --> Nov 2014 | Not yet recruiting --> Withdrawn N=10 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: May 2020 --> Aug 2016
- RG6146 / Roche
Enrollment change: A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 11, 2016
P1, N=37, Recruiting, Sponsor: Hoffmann-La Roche
N=10 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: May 2020 --> Aug 2016 N=68 --> 37
- New trial: MICROP-SMP: Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1- (clinicaltrials.gov) - Aug 11, 2016
P=N/A, N=128, Completed, Sponsor: Lille Catholic University
- || volasertib (NBL-001) / Oncoheroes, Notable Labs
Enrollment change, Combination therapy, Monotherapy: Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Aug 10, 2016
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
N=68 --> 37 N=85 --> 60
- Enrollment closed: Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Aug 10, 2016
P1/2, N=50, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
N=85 --> 60 Recruiting --> Active, not recruiting
- || Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy: A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF) (clinicaltrials.gov) - Aug 8, 2016
P1/2, N=94, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2019 --> Sep 2019
- Vonjo (pacritinib) / SOBI
Trial primary completion date: Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Aug 8, 2016
P2, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jan 2019 --> Sep 2019 Trial primary completion date: Sep 2020 --> Dec 2016
- Vonjo (pacritinib) / CTI BioPharma
Trial initiation date, Trial primary completion date, Combination therapy: Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Aug 8, 2016
P0, N=24, Not yet recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Sep 2020 --> Dec 2016 Initiation date: Feb 2016 --> Oct 2016 | Trial primary completion date: Feb 2019 --> Oct 2019
- ||| pinometostat (EPZ-5676) / Ipsen
Trial completion, Metastases: A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving (clinicaltrials.gov) - Aug 4, 2016
P1, N=51, Completed, Sponsor: Epizyme, Inc.
Initiation date: Feb 2016 --> Oct 2016 | Trial primary completion date: Feb 2019 --> Oct 2019 Active, not recruiting --> Completed
- ||||||| Besremi (ropeginterferon alfa-2b) / PharmaEssentia, AOP Orphan Pharma
Trial completion: PROUD-PV: Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (clinicaltrials.gov) - Aug 3, 2016
P3, N=256, Completed, Sponsor: AOP Orphan Pharmaceuticals AG
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | vatalanib (PTK787) / Novartis, Bayer
Trial completion: Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes (clinicaltrials.gov) - Jul 30, 2016
P2, N=155, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Familial Myeloproliferative Disorders (clinicaltrials.gov) - Jul 28, 2016
P=N/A, N=200, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Jun 2017
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial primary completion date: Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment (clinicaltrials.gov) - Jul 28, 2016
P2, N=6, Recruiting, Sponsor: Celator Pharmaceuticals
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Apr 2016 --> Dec 2016
- Trial primary completion date: Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer (clinicaltrials.gov) - Jul 28, 2016
P1, N=40, Active, not recruiting, Sponsor: California Cancer Consortium
Trial primary completion date: Apr 2016 --> Dec 2016 Trial primary completion date: Dec 2015 --> Jun 2017
- Ninlaro (ixazomib) / Takeda
Enrollment closed, Enrollment change: Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission (clinicaltrials.gov) - Jul 28, 2016
P2, N=5, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2015 --> Jun 2017 Recruiting --> Active, not recruiting | N=40 --> 5
- ||| Trial completion: Interbody Fusion Devices in the Treatment of Cervicobrachial Syndrome (clinicaltrials.gov) - Jul 26, 2016
P=N/A, N=100, Completed, Sponsor: Amedica Corporation
Recruiting --> Active, not recruiting | N=40 --> 5 Active, not recruiting --> Completed
- ||| New trial: A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (? 65 Years) With Haematologic Neoplasms (clinicaltrials.gov) - Jul 23, 2016
P=N/A, N=80, Not yet recruiting, Sponsor: Celgene Corporation
- dasatinib / Generic mfg.
Trial completion: NordCML007: Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia (clinicaltrials.gov) - Jul 19, 2016
P2, N=40, Completed, Sponsor: Norwegian University of Science and Technology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- riluzole / Generic mfg.
Trial primary completion date: Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect) (clinicaltrials.gov) - Jul 19, 2016
P3, N=270, Recruiting, Sponsor: AOSpine North America Research Network
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Jun 2017
- | Promacta (eltrombopag) / Novartis
Trial termination, Trial primary completion date, Combination therapy: A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Jul 19, 2016
P3, N=356, Terminated, Sponsor: Novartis
Trial primary completion date: Jun 2016 --> Jun 2017 Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Apr 2016
- Trial primary completion date: Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Jul 19, 2016
P1, N=40, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Apr 2016 Trial primary completion date: Jun 2019 --> Jun 2018
- azacitidine / Generic mfg.
Enrollment change, Trial withdrawal: UPCI 13-165: Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS (clinicaltrials.gov) - Jul 19, 2016
P2, N=0, Withdrawn, Sponsor: University of Pittsburgh
Trial primary completion date: Jun 2019 --> Jun 2018 N=35 --> 0 | Recruiting --> Withdrawn
- | Trial completion: Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders (clinicaltrials.gov) - Jul 19, 2016
P2, N=25, Completed, Sponsor: Beth Israel Deaconess Medical Center
N=35 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Randomized Double Cord Blood Transplant Study (clinicaltrials.gov) - Jul 18, 2016
P2, N=110, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2018 --> Jul 2016
- | topotecan / Generic mfg.
Trial completion: Topotecan in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Jul 18, 2016
P2, N=100, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | Trial primary completion date: Jun 2018 --> Jul 2016 Active, not recruiting --> Completed
- | Synribo (omacetaxine mepesuccinate) / Teva
New P1/2 trial: A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Jul 18, 2016
P1/2, N=50, Not yet recruiting, Sponsor: University of Florida
- Enrollment change, Trial withdrawal: Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (clinicaltrials.gov) - Jul 14, 2016
P2, N=0, Withdrawn, Sponsor: University of Medicine and Dentistry of New Jersey
Active, not recruiting --> Completed N=38 --> 0 | Suspended --> Withdrawn
- cytarabine / Generic mfg., decitabine / Generic mfg.
Trial completion, Phase classification, Enrollment change, Trial primary completion date: Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes (clinicaltrials.gov) - Jul 13, 2016
P1/2, N=43, Completed, Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
N=38 --> 0 | Suspended --> Withdrawn Recruiting --> Completed | Phase classification: P4 --> P1/2 | N=100 --> 43 | Trial primary completion date: Apr 2012 --> Oct 2013
- | Pegasys (pegylated interferon ? -2a) / Roche, Roferon A (recombinant interferon alfa-2a) / Roche
New P2/3 trial: A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys (clinicaltrials.gov) - Jul 12, 2016
P2/3, N=9, Completed, Sponsor: Hoffmann-La Roche
- ||||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte
New P1/2 trial: Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Jul 12, 2016
P1/2, N=132, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| imatinib / Generic mfg.
Trial completion, Trial primary completion date: Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML) (clinicaltrials.gov) - Jul 12, 2016
P=N/A, N=150, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed | Phase classification: P4 --> P1/2 | N=100 --> 43 | Trial primary completion date: Apr 2012 --> Oct 2013 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Dec 2012
- ||| Trial completion: ARIE: Bone Pain Score Validation Initiative (clinicaltrials.gov) - Jul 12, 2016
P=N/A, N=370, Completed, Sponsor: iOMEDICO AG
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Dec 2012 Active, not recruiting --> Completed
- gedatolisib (PF-05212384) / Celcuity
Enrollment open: LAM-PIK: PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Jul 11, 2016
P2, N=39, Recruiting, Sponsor: Institut Curie
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Epogen (epoetin alfa) / Amgen
Trial completion: Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy (clinicaltrials.gov) - Jul 11, 2016
P3, N=344, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Recruiting No longer recruiting --> Completed
- | pracinostat (SB939) / Helsinn, MEI, Menarini
Trial completion, P2 data: Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA (clinicaltrials.gov) - Jul 6, 2016
P2, N=45, Completed, Sponsor: MEI Pharma, Inc.
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Rydapt (midostaurin) / Novartis
Trial completion: Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 6, 2016
P1, N=34, Completed, Sponsor: Alison Walker
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | ondansetron / Generic mfg.
Trial completion, Metastases: Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment (clinicaltrials.gov) - Jul 4, 2016
P3, N=100, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Tasigna (nilotinib) / Novartis, Inhibikase
Trial primary completion date: Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Jul 1, 2016
P2, N=40, Active, not recruiting, Sponsor: Cancer Trials Ireland
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> Dec 2016
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion, Trial primary completion date: Multicenter Transplant Study for Fanconi Anemia (clinicaltrials.gov) - Jun 29, 2016
P2, N=45, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Trial primary completion date: May 2016 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Jul 2015
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer (clinicaltrials.gov) - Jun 29, 2016
P2, N=82, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Jul 2015 Active, not recruiting --> Completed
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed, Minimal residual disease: Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 27, 2016
P1, N=54, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial primary completion date: APCORD: Cord Blood Transplantation in Severe Aplastic Anemia (clinicaltrials.gov) - Jun 25, 2016
P2, N=26, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2015 --> Nov 2016
- | Vonjo (pacritinib) / SOBI
New P1 trial: PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects (clinicaltrials.gov) - Jun 21, 2016
P1, N=40, Completed, Sponsor: CTI BioPharma
- Januvia (sitagliptin) / Merck (MSD)
Trial primary completion date: Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant (clinicaltrials.gov) - Jun 20, 2016
P2, N=74, Recruiting, Sponsor: Sherif S. Farag
Trial primary completion date: Nov 2015 --> Nov 2016 Trial primary completion date: Nov 2015 --> Nov 2017
- Jakafi (ruxolitinib) / Novartis, Incyte
New P1/2 trial, Post-transplantation: PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis (clinicaltrials.gov) - Jun 20, 2016
P1/2, N=20, Recruiting, Sponsor: St. Petersburg State Pavlov Medical University
- Sylvant (siltuximab) / Jazz
New trial: Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov) - Jun 20, 2016
P0, N=12, Not yet recruiting, Sponsor: Northwestern University
- Enrollment closed: Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) (clinicaltrials.gov) - Jun 18, 2016
P2, N=279, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Nov 2015 --> Nov 2017 Recruiting --> Active, not recruiting
- Tasigna (nilotinib) / Novartis, Inhibikase
Trial initiation date, Trial primary completion date: Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia (clinicaltrials.gov) - Jun 18, 2016
P2, N=100, Not yet recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting Initiation date: May 2016 --> Dec 2016 | Trial primary completion date: May 2019 --> Dec 2019